Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Ortho Clinical Diagnostics
Thumbnail
May 06, 2022

For medtechs seeking deals, it’s hurry up and wait

Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.

Thumbnail
January 20, 2022

Medical device groups float – then sink

Medtechs rushed for the markets last year, but had an uneasy time once there.

Article image
Vantage logo
December 31, 2021

Medtech developments over the Christmas period

The FDA scrambles for more rapid Covid-19 tests, and the device sector enjoys a late flurry of deals.

Article image
Vantage logo
July 14, 2021

Floating medtechs go big or go home

IPOs in the medical device sector are bigger than in biotech, but performance, at least of the biggest groups, is mixed.

Article image
Vantage logo
January 29, 2021

Ortho Clinical takes a haircut

Discount pricing and poor first day defies the recent trend for floating device makers.

Article image
Vantage logo
June 18, 2020

The FDA gets aggressive with Covid-19 antibody tests

Chembio’s antibody test is the first to have its authorisation revoked. It might not be the last.

Article image
Vantage logo
May 04, 2020

Roche takes on Abbott in Covid-19 antibody testing

Robust specificity data mark Roche’s serological test out as a major competitor.

Article image
Vantage logo
April 22, 2020

Covid-19 antibody tests face a very specific problem

With the prevalence of coronavirus infection running at about 5%, test manufacturers and regulators alike will have to guard against false positives.

Article image
Vantage logo
March 10, 2020

Few groups have developed Covid-19 diagnostics – but this will change

The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.

Vantage logo
January 20, 2016

J&J device refocus continues with 3,000 job cuts

Vantage logo
October 14, 2015

Interview – J&J looks to external innovation to secure the future

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 15, 2022

Q2 Roundp Medtech Infographic

August 12, 2022

Q2 Roundup Pharma Infographic

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.

Open modal